Alnylam price target raised to $330 from $310 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Alnylam (ALNY) to $330 from $310 and keeps an Outperform rating on the shares. The FDA has approved Amvuttra for transthyretin-mediated amyloidosis, and while there are clearly some puts and takes in the label, the FDA was rational despite its “complex history” with the company and the label generally reflects the meaningful clinical benefit seen in HELIOS-B, the analyst tells investors in a research note. This is “close to best case scenario” for the company, and the firm remains buyers given an upcoming launch in a $6B market where 90% of patients are yet to be on therapy, the firm added.